Novartis India [NOVARTIND] vs Gujarat Themis [GUJTHEM] Detailed Stock Comparison

Novartis India Ltd.

BSE
Loading...

Gujarat Themis Biosyn Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Novartis India Ltd. wins in 12 metrics, Gujarat Themis Biosyn Ltd. wins in 8 metrics, with 0 ties. Novartis India Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Novartis India Ltd. Gujarat Themis Biosyn Ltd. Better
P/E Ratio (TTM) 25.00 73.73 Novartis India Ltd.
Price-to-Book Ratio 3.14 13.36 Novartis India Ltd.
Debt-to-Equity Ratio 0.52 27.04 Novartis India Ltd.
PEG Ratio -1.18 -17.55 Novartis India Ltd.
EV/EBITDA 20.21 52.76 Novartis India Ltd.
Profit Margin (TTM) 27.97% 29.99% Gujarat Themis Biosyn Ltd.
Operating Margin (TTM) 25.47% 40.16% Gujarat Themis Biosyn Ltd.
EBITDA Margin (TTM) 25.47% 40.16% Gujarat Themis Biosyn Ltd.
Return on Equity 12.85% 19.64% Gujarat Themis Biosyn Ltd.
Return on Assets (TTM) 10.65% 16.19% Gujarat Themis Biosyn Ltd.
Free Cash Flow (TTM) $745.70M $-251.22M Novartis India Ltd.
Dividend Yield 2.44% 0.17% Novartis India Ltd.
1-Year Return 49.33% 31.69% Novartis India Ltd.
Price-to-Sales Ratio (TTM) 7.00 22.23 Novartis India Ltd.
Enterprise Value $18.37B $36.09B Gujarat Themis Biosyn Ltd.
EV/Revenue Ratio 5.29 22.65 Novartis India Ltd.
Gross Profit Margin (TTM) 43.07% 83.29% Gujarat Themis Biosyn Ltd.
Revenue per Share (TTM) $141 $15 Novartis India Ltd.
Earnings per Share (Diluted) $39.42 $4.40 Novartis India Ltd.
Beta (Stock Volatility) -0.05 -0.17 Gujarat Themis Biosyn Ltd.

Novartis India Ltd. vs Gujarat Themis Biosyn Ltd. Stock Performance Analysis

Loading Price Chart...

NOVARTIND
GUJTHEM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Novartis India Ltd.-9.47%-10.87%29.78%44.07%63.91%70.30%
Gujarat Themis Biosyn Ltd.1.72%-7.03%7.92%39.85%0.71%-8.80%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Novartis India Ltd.49.33%115.71%137.09%117.42%110.10%222.44%
Gujarat Themis Biosyn Ltd.31.69%84.69%84.69%84.69%84.69%84.69%

Performance & Financial Health Analysis: Novartis India Ltd. vs Gujarat Themis Biosyn Ltd.

MetricNOVARTINDGUJTHEM
Market Information
Market Cap i₹23.65B₹35.41B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i10,69379,452
90 Day Avg. Volume i14,037106,446
Last Close₹1,326.20₹401.80
52 Week Range₹750.00 - ₹1,588.40₹225.05 - ₹479.00
% from 52W High-16.51%-16.12%
All-Time High₹1,588.40 (Jun 01, 2026)₹479.00 (Oct 27, 2025)
% from All-Time High-16.51%-16.12%
Growth Metrics
Quarterly Revenue Growth-0.08%0.10%
Quarterly Earnings Growth-0.37%-0.04%
Financial Health
Profit Margin (TTM) i0.28%0.30%
Operating Margin (TTM) i0.25%0.40%
Return on Equity (TTM) i0.13%0.20%
Debt to Equity (MRQ) i0.5227.04
Cash & Liquidity
Book Value per Share (MRQ)₹313.93₹24.29
Cash per Share (MRQ)₹250.14₹0.92
Operating Cash Flow (TTM) i₹997.00M₹970.68M
Levered Free Cash Flow (TTM) i₹1.01B₹487.72M
Dividends
Last 12-Month Dividend Yield i2.44%0.17%
Last 12-Month Dividend i₹25.00₹0.67

Valuation & Enterprise Metrics Analysis: Novartis India Ltd. vs Gujarat Themis Biosyn Ltd.

MetricNOVARTIND (Apr 24, 2026)GUJTHEM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i25.0073.73
Forward P/E iN/AN/A
PEG Ratio i-1.18-17.55
Price to Sales (TTM) i7.0022.23
Price to Book (MRQ) i3.1413.36
Market Capitalization
Market Capitalization i₹23.65B₹35.41B
Enterprise Value i₹18.37B₹36.09B
Enterprise Value Metrics
Enterprise to Revenue i5.2922.65
Enterprise to EBITDA i20.2152.76
Risk & Other Metrics
Beta i-0.05-0.17
Book Value per Share (MRQ) i₹313.93₹24.29

Financial Statements Comparison: Novartis India Ltd. vs Gujarat Themis Biosyn Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNOVARTIND (2025)GUJTHEM (2025)
Revenue/Sales i3.56B1.51B
Cost of Goods Sold i2.06B318.78M
COGS % of Revenue i57.7%21.1%
Gross Profit i1.51B1.19B
Gross Margin i42.3%78.9%
Research & Development iN/A34.37M
Operating Income (EBIT) i941.70M642.49M
Operating Margin i26.4%42.6%
EBITDA i1.38B713.04M
EBITDA Margin i38.7%47.3%
Pre-Tax Income i1.30B655.38M
Pre-Tax Income % of Revenue i36.6%43.5%
Income Tax i295.20M167.66M
Income Tax % of Revenue i8.3%11.1%
Net Income (Profit) i1.01B487.72M
Profit Margin i28.3%32.3%

Balance Sheet & Liquidity Metrics

MetricNOVARTIND (2025)GUJTHEM (2025)
Cash & Equivalents i520.70M116.94M
Total Current Assets i7.46B519.73M
Total Current Assets % of Revenue i209.3%34.5%
Total Current Liabilities i1.42B205.60M
Total Current Liabilities % of Revenue i39.9%13.6%
Long-Term Debt i32.10M296.36M
Long-Term Debt % of Revenue i0.9%19.7%
Total Shareholders Equity i7.85B2.48B
Retained Earnings i7.69B2.37B
Retained Earnings % of Revenue i215.8%157.4%
Property, Plant & Equipment i35.70M411.30M

Cash Flow Statement Comparison

MetricNOVARTIND (2025)GUJTHEM (2025)
Operating Cash Flow i997.00M970.68M
Operating Cash Flow % of Revenue i28.0%64.4%
Capital Expenditures i3.20M-1.16B
Free Cash Flow i745.70M-251.22M
FCF Margin i20.9%-16.7%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNOVARTINDGUJTHEM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i24.69M108.97M
Float Shares i6.69M29.52M
% Held by Insiders i72.92%71.98%
% Held by Institutions i0.16%1.18%
% Held by Public i26.92%26.84%

Dividend Analysis & Yield Comparison: Novartis India Ltd. vs Gujarat Themis Biosyn Ltd.

MetricNOVARTINDGUJTHEM
Last 12-Month Dividend i₹25.00₹0.67
Last 12-Month Dividend Yield i2.44%0.17%
3-Year Avg Annual Dividend i₹32.50₹0.22
3-Year Avg Dividend Yield i3.57%0.17%
3-Year Total Dividends i₹97.50₹0.67
Ex-Dividend DateJul 23, 2025Sep 04, 2025